Latest News

Asia-Pacific $100+ Mn Nonalcoholic Steatohepatitis Therapeutics Markets to 2024 – ResearchAndMarkets.com





DUBLIN–(BUSINESS WIRE)–The "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 – Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering. The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%. Over the forecast period the prevalence of Non-Alcoholic Steato-Hepatitis (NASH) is expected to increase significantly across the APAC ma

Source link





Related posts

GE Healthcare showcases new Edison applications and Edison-powered devices at RSNA 2018

Newsemia

Driving Factors of Agricultural Virtual Water Trade between China and the Belt and Road Countries

Newsemia

Medical News Today: Causes and treatments for a burning chest

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy